2021-08-162021-08-162021-06-28RODRIGUES, Jéssica Alves. Resistência da Helicobacter pylori aos antibióticos utilizados em diferentes esquemas terapêuticos: uma revisão integrativa. 2021. 33 f. Trabalho de Conclusão de Curso (Graduação) - Faculdade de Farmácia, Universidade Federal de Goiás, Goiânia, 2021.http://repositorio.bc.ufg.br/handle/ri/19763Helicobacter pylori is a gram-negative bacterium with the ability to colonize the gastric mucosa. It is estimated that the microorganism affects more than half of the world's population. Eradication is performed with first-line triple therapy consisting of a combination of a proton pump inhibitor and two antibiotics, which are important to reduce the onset of infection-related gastric diseases such as gastritis, ulcers and gastric cancer. The increase in bacterial resistance has become a major public health problem. Due to the high resistance rates, H. pylori was considered by the World Health Organization as one of the main bacteria that need new strategies for drug development. The aim of this study was to describe the pattern of resistance of H. pylori to antibiotics used in different therapeutic regimens. This is an integrative review, whose articles were surveyed in the PubMed, LILACS, Science Direct and SciElo databases. The inclusion criteria were studies published in Portuguese and English, indexed in those databases in the last ten years, with free access in full and that addressed the theme. The results showed mean resistance rates to metronidazole of 47.6%, levofloxacin of 24.7% and clarithromycin of 24.6%. For tetracycline and amoxicillin the means were 1.5% and 0.9% respectively. These results demonstrate varying patterns of resistance and reinforce the need to develop new drugs. It is concluded that the abusive use of antibiotics has led to increased resistance of H. pylori to the antibiotics used in its eradication.porAcesso AbertoHelicobacter pyloriResistênciaAntibióticosTratamentoResistanceAntibioticsTreatmentTCC